As of Friday close, ImmunoGen Inc.’s (NASDAQ:IMGN) stock was down -$0.16, moving down -1.07 percent to $14.77. The average number of shares traded per day over the past five days has been 3,502,680 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.95 fall in that time frame. In the last twenty days, the average volume was 3,362,935, while in the previous 50 days, it was 4,416,108.
Since last month, IMGN stock retreated -9.11%. Shares of the company fell to $14.41 on 09/21/23, the lowest level in the past month. A 52-week high of $20.69 was reached on 07/19/23 after having rallying from a 52-week low of $3.61. Since the beginning of this year, IMGN’s stock price has risen by 197.78% or $9.81, and marked a new high 20 times. However, the stock has declined by -28.61% since its 52-week high.
IMGN stock investors should be aware that ImmunoGen Inc. (IMGN) stock had its last reported insider trading activity 8 days ago on Sep 15. Wingrove Theresa, the SVP OF REGULATORY AFFAIRS of the company, disposed of 192,013 shares for $15.44 on Sep 15. It resulted in a $2,964,681 divestment by the insider. Coen Stacy Ann sold 100,210 shares at an average price of $14.20 on Aug 09. The insider now owns 10,960 shares following the transaction. On Aug 04, CHIEF EXECUTIVE OFFICER Enyedy Mark J sold 992,397 shares at $16.96 apiece. The transaction was valued at $16,831,053.
Valuation Metrics
The stock’s beta is 1.01. Besides these, the trailing price-to-sales (P/S) ratio of 19.44, the price-to-book (PB) ratio of 7.94.
Financial Health
In the three months ended June 29, ImmunoGen Inc.’s quick ratio stood at 7.10, while its current ratio was 7.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.15, and the total debt-to-equity ratio was 0.15. On the profitability front, the trailing twelve-month gross margin is 99.10% percent. In the year ended June 29, EBITDA margin amounted to -201.42%, whereas operating margins totaled -96.80%. Based on annual data, IMGN earned $108.61 million in gross profit and brought in $108.78 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -142.60%. Return on equity (ROE) for the past 12 months was -76.90%.
In ImmunoGen Inc.’s quarter-end financial report for June 29, it reported total debt of $71.96 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. IMGN’s revenue rose 82.97% to $49.87 million during the quarter, while net income inched up to $83.15 million. While analysts expected ImmunoGen Inc. to report -$0.14 quarterly earnings, the actual figure was -$0.02 per share, beating the consensus estimate by 85.70%. During the quarter, the company generated -$3.76 million in EBITDA. The liabilities of ImmunoGen Inc. were 223.49 million at the end of its most recent quarter ended June 29, and its total debt was $85.21 million. The value of shareholders’ equity is $248.94 million.
Technical Picture
This quick technical analysis looks at ImmunoGen Inc.’s (IMGN) price momentum. With a historical volatility rate of 40.01%, the RSI 9-day stood at 33.96% on 22 September.
With respect to its five-day moving average, the current ImmunoGen Inc. price is down by -6.04% percent or -$0.95. At present, IMGN shares trade -7.11% below its 20-day simple moving average and +168.06% percent above its 100-day simple moving average. However, the stock is currently trading approximately -21.52% below its SMA50 and +172.01% above its SMA200.
Stochastic coefficient K was 15.21% and Stochastic coefficient D was 21.93%, while ATR was 0.63. Given the Stochastic reading of 17.78% for the 14-day period, the RSI (14) reading has been calculated as 38.21%. As of today, the MACD Oscillator reading stands at -0.61, while the 14-day reading stands at -0.68.
Analyst Ratings
Piper Sandler upgraded its rating on ImmunoGen Inc. (NASDAQ: IMGN) to an Overweight in a note to investors on May 03, 2023. The analysts firm previously had a Neutral rating on the stock.ImmunoGen Inc. (IMGN) has been rated Buy by analysts. According to 0 brokerage firms, IMGN is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate ImmunoGen Inc. stock as buy, with 10 recommending it as overweight.
With a median target price of $24.00, the current consensus forecast for the stock is $13.00 – $27.00. Based on these forecasts, analysts predict ImmunoGen Inc. (IMGN) will achieve an average price target of $22.90.
